ReviewPharmacology & therapeutics2022
Neurosteroids (allopregnanolone) and alcohol use disorder: From mechanisms to potential pharmacotherapy.
Review in Pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Pregnenolone effects on parasympathetic response to stress and alcohol cue provocation in treatment-seeking individuals with alcohol use disorder.Alcohol, clinical & experimental research · 2025Trial
- Naltrexone treatment improves anxiety- and depression-like behavior in alcohol-exposed mice.Behavioural pharmacology · 2026Article
- Impact of impaired endogenous neurosteroidogenesis on outcomes following chronic alcohol exposure.bioRxiv : the preprint server for biology · 2026Article
- The role of neuroactive steroids in psychiatric and neurological disorders: Neurobiology and therapeutic perspectives.Neuroscience and biobehavioral reviews · 2025Review
- Microbiome modulation as a therapeutic strategy for alcohol-induced gut dysbiosis and associated disorders.Antonie van Leeuwenhoek · 2025Review
- Structural modifications to pregnane neurosteroids alter inhibition of LPS/Lipid A binding at the MD-2 activation site within the TLR4 signaling complex.Frontiers in immunology · 2025Article
- Sex and sobriety: Human brain structure and function in AUD abstinence.Alcohol (Fayetteville, N.Y.) · 2024Review
- Stability and Reliability of Repeated Plasma Pregnenolone Levels After Oral Pregnenolone Dosing in Individuals with Cocaine Use Disorder: Pilot Findings.Life (Basel, Switzerland) · 2024Article
- Stress and substance use disorders: risk, relapse, and treatment outcomes.The Journal of clinical investigation · 2024Review
- The role of neurosteroids in posttraumatic stress disorder and alcohol use disorder: A review of 10 years of clinical literature and treatment implications.Frontiers in neuroendocrinology · 2024Review
- Potential Link Between Exercise and N-Methyl-D-Aspartate Glutamate Receptors in Alcohol Use Disorder: Implications for Therapeutic Strategies.Psychology research and behavior management · 2024Review
- GABAergic compounds for the treatment of alcohol use disorder.International review of neurobiology · 2024Review
- Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities.Pharmacology & therapeutics · 2023Review
- Therapeutic strategies of small molecules in the microbiota-gut-brain axis for alcohol use disorder.Drug discovery today · 2023Review
- Gender and Neurosteroids: Implications for Brain Function, Neuroplasticity and Rehabilitation.International journal of molecular sciences · 2023Review
- GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential.Frontiers in neural circuits · 2023Review
- Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials.Expert review of clinical pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Alcohol Use Disorder (AUD) is a multifaceted relapsing disorder that is commonly comorbid with psychiatric disorders, including anxiety. Alcohol exposure produces a plethora of effects on neurobiology. Currently, therapeutic strategies are limited, and only a few treatments - disulfiram, acamprosate, and naltrexone - are available. Given the complexity of this disorder, there is a great need for the identification of novel targets to develop new pharmacotherapy. The GABAergic system, the primary inhibitory system in the brain, is one of the well-known targets for alcohol and is responsible for the anxiolytic effects of alcohol. Interestingly, GABAergic neurotransmission is fine-tuned by neuroactive steroids that exert a regulatory role on several endocrine systems involved in neuropsychiatric disorders including AUD. Mounting evidence indicates that alcohol alters the biosynthesis of neurosteroids, whereas acute alcohol increases and chronic alcohol decreases allopregnanolone levels. Our recent work highlighted that chronic alcohol-induced changes in neurosteroid levels are mediated by epigenetic modifications, e.g., DNA methylation, affecting key enzymes involved in neurosteroid biosynthesis. These changes were associated with changes in GABA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.